Neural stem cells (NSCs) are being investigated as a possible treatment for amyotrophic lateral sclerosis (ALS) through intraspinal transplantation, but no longitudinal imaging studies exist that describe the survival of engrafted cells over time. Allogeneic firefly luciferase-expressing murine NSCs (Luc + -NSCs) were transplanted bilaterally (100,000 cells/2 μl) into the cervical spinal cord (C5) parenchyma of pre-symptomatic (63 day-old) SOD1
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that is characterized by the progressive loss of motor neurons. The motor neuron degeneration leads to paralysis, respiratory failure, and death within three to five years from disease onset (Chio et al., 2009; Chio et al., 2013) . The pathomechanisms of motor neuron degeneration are poorly understood (Boillee et al., 2006) , and there is only one FDAapproved drug that marginally extends the life expectancy of ALS patients by three to four months (Bensimon et al., 1994) . A long duration between the onset of pathological changes and the manifestation of clinical symptoms in ALS complicates the management of this disease. Considering the complexity of the disease, the development of a therapy that can maintain or restore motor neuron function would provide the most comprehensive approach to treating ALS (Chen et al., 2016) .
In the last decade, several preclinical studies showed promising outcomes using stem cells in ALS transgenic animal models (Teng et al., 2012; Xu et al., 2011) . In 2009, the FDA approved the first clinical safety trial of direct intraspinal transplantation of human NSCs into patients with ALS Riley et al., 2012) . One of the major obstacles in successful stem cell therapy is the short-term survival of engrafted cells due to immune rejection (Barker and Widner, 2004) . In ALS, several factors can lead to the rejection of transplanted stem cells. For example, disease progression in ALS is accompanied by a multi-phased immune response, and this plays an active role in shaping ALS pathology (Alexianu et al., 2001; Chiu et al., 2009; Yamanaka et al., 2008) . An inevitable inflammation due to invasive cell transplantation Experimental Neurology 289 (2017) [96] [97] [98] [99] [100] [101] [102] surgery, and the resultant local trauma, could also influence the survival of engrafted therapeutic cells. In addition to the ability to determine long-term survival and the functionality of transplanted cells, realtime information on the accuracy of cell transplantation and adverse outcomes, such as teratoma formation and migration of cells to inappropriate locations, could also greatly affect the outcome of therapy. The current histological methods to analyze transplanted cells are invasive, require euthanasia of the animal, and limit our ability to monitor engrafted cells in real-time over an elongated period of time. In a phase 1/2 open label clinical safety trial, iron oxide-labeled MSCs were injected and tracked in the central nervous system (CNS) by MRI in multiple sclerosis (MS) and ALS patients (Karussis et al., 2010) . However, this approach is only suitable for short-term monitoring of immediate cell engraftment, and not for imaging cell survival (Srivastava and Bulte, 2014) . Teng et al. (2012) showed that the most potent therapeutic effect for a multi-level NSC transplantation approach is to escalate cell dose, indicating the importance of administrating sufficient cell numbers into critically functioning spinal cord segments to combat ALS pathology. It is therefore pivotal to develop longitudinal imaging strategies to monitor donor cell fate for devising cell therapies for ALS.
In this study, we used two different imaging modalities, computed tomography (CT) and bioluminescence imaging (BLI), to non-invasively visualize the accuracy of cell transplantation and to longitudinally monitor the survival of intraspinally transplanted murine Luc + -NSCs in a transgenic SOD1
G93A mouse model of ALS during disease progression.
Materials and methods

Isolation of NSCs
All animal procedures were approved and conducted in accordance with the guidelines of our Institutional Animal Care and Use Committee (IACUC). Animals were maintained in a normal day-night cycle (12/ 12 hr) with access to food and water ad libitum. Allogeneic Luc + -NSCs were isolated from the brain of a homozygous firefly luciferase transgenic mouse (FVB background, Jackson Laboratory, Bar Harbor, ME, stock # 008450) at the E13.5 stage as previously described (Ferrari et al., 2010) . Briefly, cells were maintained in serum-free DMEM/F12 medium (Invitrogen, Carlsbad, CA) supplemented with 10 ng/ml epidermal growth factor (EGF; Invitrogen) and 10 ng/ml basic fibroblast growth factor (bFGF; Invitrogen). After seven days of culture, cells had grown to free-floating neurospheres. For passaging, spheres were dissociated using 1 ml Accutase (Life Technologies) for 10 min at room temperature. Single cells were resuspended in the same medium.
BLI of Luc
+ -NSCs in vitro
Luc + -NSCs were plated into poly L-lysine/laminin-coated 96-well plates at 10,000, 1000, and 100 cells per well. For bioluminescence (BL) signal measurements, the medium was removed and 30 mg/ml D-luciferin (Sigma-Aldrich, St. Louis, MO) in 10 mM phosphate buffered saline (PBS), pH = 7.4 was added. The BL signal was measured using an IVIS SpectrumCT In Vivo Imaging System (Perkin Elmer, Waltham, MA). Images were acquired at one-minute intervals for 10 min until peak signal was observed. BL signal was quantified by the creation of regions of interests (ROIs) over the wells, with the data expressed as photon flux (p/s).
Cell preparation for transplantation
On the day of transplantation, neurospheres were collected, washed with PBS, and then treated with 1 ml Accutase (Life Technologies, Carlsbad, CA) for 10 min at room temperature to make a single cell suspension. The cells were then centrifuged at 200xg for five minutes and the supernatant was removed. The cell pellet was resuspended in PBS and the cell number was determined using an automated cell counter (Cellometer Auto 2000, Nexcelom Bioscience, Lawrence, MA).
Immunosuppression
Mice were immunosuppressed by intraperitoneal (i.p.) daily administration of a cocktail of tacrolimus (FK-506) + sirolimus (Rapamycin) (1 mg/kg each; LC Laboratories; Woburn, MA), beginning five days before cell transplantation, and then, continuously until sacrifice.
Cell transplantation
Twenty male SOD1
G93A ALS mice (B6SJL-Tg(SOD1*G93A)1Gur/J:
Stock # 002726) (Jackson Laboratory) and 14 male wild-type littermates were used in this study. The animals were divided into three groups: (i) SOD1 G93A ALS mice (n = 14) transplanted with Luc + -NSCs; (ii) wild-type littermates (n = 14) transplanted with Luc + -NSCs; and (iii) control SOD1 G93A ALS mice (n = 6) injected with PBS.
Cells were transplanted in the cervical spinal cord region of 63-day old mice as previously described (Lepore et al., 2011) . In brief, animals were anesthetized with 350 mg/kg chloral hydrate i.p. (Sigma). Each mouse received two grafts (bilaterally at the C5 cervical spinal cord region) of 100,000 NSCs/site (in 2 μL saline) into the ventral horn. Control SOD1 G93A ALS mice were injected with only 2 μL saline/site into the ventral horn. Cells were delivered using a 10 μL Hamilton Gastight syringe with an attached 30-gauge 45°beveled needle (Hamilton; Reno, NV). The injection pipette was secured to a manual micromanipulator (World Precision Instruments; Sarasota, FL) attached to an 80°tilting base. The tip was lowered to a depth of 0.75 mm below the surface of the cord and was held in place for two minutes before and after cell injection to minimize backflow. Cells were delivered under the control of a micro-syringe pump controller (World Precision Instruments) at a rate of 0.5 μl/min.
Computed tomography
CT images were acquired with an IVIS SpectrumCT In Vivo Imaging System (Perkin Elmer) using 50 kVp X-rays at 1 mA of current, 50 ms exposure time, and with an aluminum filter. A total of 720 projections, spaced 0.5°apart, were acquired and the CT volume was reconstructed using Living Image 4.3 software (Perkin Elmer), which provided a field of view (FOV) of 12.0 × 12.0 × 3.0 cm and an isotropic resolution of 0.15 mm.
BLI of intraspinally engrafted Luc
+ -NSCs
Bioluminescent images of the animals were acquired using the cooled CCD camera of the same IVIS SpectrumCT instrument. For each animal, anesthesia was induced using 2% isoflurane gas in oxygen, and 150 mg/kg body weight of D-luciferin (Sigma-Aldrich) was injected i.p.. Images were acquired 10 min after injection to maximize the BL signal. To generate two-dimensional (2D) bioluminescent images, no emission filter was used during imaging. Images were quantified by drawing ROIs over the cervical spinal cord region and the data were expressed as photon flux (p/s). To generate three-dimensional (3D) bioluminescent images, four spectrally resolved images were acquired using emission filters at 600, 620, 640, and 660 nm, with a bandwidth of 20 nm each. Imaging parameters were an exposure time of 180 s, an aperture of f/1, a FOV = 13 cm, and 2048 × 2048 pixel resolution. Pixel binning was set to an 8 × 8 bin width for an effective image resolution of 256 × 256 pixels. Imaging parameters were identical for both 2D and 3D imaging.
Three-dimensional micro-CT/BLI reconstruction
Three-dimensional reconstruction of the bioluminescent source and superposition over the CT images was achieved with the diffuse light imaging tomographic (DLIT) algorithm available in Living Image 4.3 software. This software predefines the bioluminescent source and tissue absorption spectra for the luciferase reporter and mouse tissue. The source distribution was visualized using a voxel size of 0.31 mm without smoothing.
Disease onset and end-stage assessment
Mice were observed for weight loss and visible signs of weakness in splaying the hind limb to determine disease onset. To determine disease end-stage in a humane manner, the end-stage was defined as the inability of mice to right themselves within 30 s when placed on their side.
Rotarod test
For behavioral analysis, the motor performance of animals was evaluated using a Rotarod apparatus (7650 accelerating model, Ugo Basile, Varese, Italy). Mice were placed on the accelerating rod at a starting speed of 4 rpm, reaching a final speed of 40 rpm in three minutes. All mice underwent three trials. The mice were allowed to stay on the rod for a maximum of 120 s and the time of their hold on the rod was scored.
Tissue preparation and immunohistochemistry
Animals were anesthetized and perfused intracardially with 4% paraformaldehyde in PBS. Spinal cords were extracted, post-fixed in the same solution overnight at 4°C, and cryopreserved in 30% sucrose. Frozen transverse sections, 30 μm thick, were cut using a Thermo Scientific HM 550 cryostat. For immunohistochemical analysis, non-specific binding was blocked by incubating with a solution consisting of 10% donkey serum and 0.1% Triton X-100 in PBS for two hours at room temperature. Sections were incubated overnight at 4°C with the appropriate dilution of primary antibody in blocking solution. Primary antibodies used were: Anti-firefly luciferase (1:3000 dilution, GeneTex, Irvine, CA); anti-GFAP (1:1000, Santa Cruz Biotechnology, Santa Cruz, USA); anti-Iba1 (1:1000, Wako Diagnostics, Richmond, VA); anti-Olig2 (1:250, Santa Cruz); anti-NeuN (1:500 dilution, EMD Millipore, Billerica, MA); and anti-F4/80 (1:250, Abcam, Cambridge, MA). The corresponding fluorescent secondary antibodies Alexa Fluor-488 and Alexa Fluor-546 (Invitrogen) were added at 1:200 dilution in blocking solution for two hours at room temperature. Sections were then rinsed with 0.1 M PBS and placed on coverslips with aqueous non-fluorescent mounting medium (Immu-mount, Thermo Scientific, Pittsburgh, PA). Images were obtained with a Zeiss AX10 fluorescence microscope. All images were obtained using the same exposure time.
Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM). Statistical analysis was performed using GraphPad Prism software (version 6.0). Linear regression analysis was performed to determine the correlation between two variables. Student's t-test was used with a significance level set at p b 0.05.
Results
Initial validation studies
In vitro BLI analysis of Luc + -NSCs plated at different cell densities showed a linear correlation between cell number and BLI signal (R 2 = 0.99, Fig. 1 ), validating the use of BLI for quantification of luciferase-expressing NSCs. For validation of accurate placement of cells at the target site, in vivo 3D BLI and CT images were co-registered on 1 day post cell transplantation. An accurate overlay of the cellular BLI signal with the anatomical location of the C5 cervical spinal cord region was observed (Fig. 2) . 
Motor performance and weight loss
SOD1
G93A ALS mice displayed a typical pattern of disease progression, as evidenced by the presence of neurological deficits in motor behavior and a reduction in body weight. Compared to saline-injected animals, in mice engrafted with NSCs alone, a significant but transient improvement in motor performance was observed only at the early stages of the disease (Fig. 3) . There was no significance difference in weight loss between the two groups. There was a further decline in the BLI signal intensity as the disease progressed, and signal was completely lost at the post-symptomatic stage of the disease (8 weeks post-transplantation). In contrast, in wild-type littermates, the BLI signal was still detectable (42.14 ± 8.7%), indicating that almost half of the transplanted cells were able to survive in wild-type mice (Fig. 4) . Prolonged survival of grafted cells in wild-type mice was further confirmed by histology (Fig. 5) (Fig. 6) .
Survival of Luc
Host immune environment
Activated glial cells and immune cells could be detected in the spinal cord parenchyma around the site of cell transplantation. Higher degrees of microgliosis and astrogliosis were observed in the spinal cord of SOD1 G93A ALS mice compared to wild-type littermates at the postsymptomatic stage of the disease (Fig. 5) . A high expression of F4/80, a marker for mature mouse macrophages, was observed in the ventral horn of the cervical spinal cord of SOD1 G93A ALS mice, whereas wildtype littermates had much fewer of these resident macrophages (Fig. 7) .
Discussion
ALS is an incurable and fatal disease, characterized by the rapid and selective death of both upper and lower motor neurons. Therapeutic grafting of NSCs has proven to be one of the most promising approaches to replace and/or protect dying neurons (Fischer, 2000) . NSC engraftment not only results in the replacement of neurons and glia cells, but may also improve functional outcomes through bystander mechanisms, such as neurotrophism (Barnabe-Heider and Miller, 2003; Lu et al., 2003) . However, one of the major challenges in the therapeutic use of NSCs is potential graft rejection (Hefferan et al., 2011; Jablonska et al., 2013; Kim et al., 2006; Li et al., 2005; Tambuyzer et al., 2009; Yan et al., 2006) . Graft rejection could result either by pathogenic immune signaling that results from the disease process itself (Chen and Palmer, 2008) , or by an adaptive host immune response immediately after cell engraftment (Zhao et al., 2011) .
To the best of our knowledge, there have been no systematic in vivo studies on the survival of transplanted cells as related to the progression of ALS disease symptoms. In this study, we non-invasively imaged allogeneic murine Luc + -NSCs engrafted in the spinal cord of SOD1 G93A ALS mice, and found that the survival of cells was greatly reduced with disease progression. The high sensitivity, low background signal, and non-invasive nature of BLI allowed us to quantitatively assess the viability of engrafted cells in animals at various time points during the course of the disease, without the need for animal euthanasia and tissue harvesting (Srivastava et al., 2016) . As visualized by co-registered BLI/CT imaging, we were able to accurately reproduce cell injection at the targeted cervical spinal cord region site without spillover to distal regions.
In this study, we used allogeneic murine NSCs as allogeneic cells offer the most practical source for cell therapy of neurodegenerative disorders in a clinical setting Mazzini et al., 2015) . We observed that, after engraftment, Luc . This finding is in agreement with a previous study by Tadesse et al., in which the authors reported that human NSCs engrafted in the spinal cord of ALS patients maintained their stem cell phenotypes even after 2.5 years of transplantation (Tadesse et al., 2014) . The reason for this lack of differentiation is unclear, and may be a function of complexities intrinsic to the ALS spinal cord microenvironment. After a transient early increase at the onset of disease, we observed a dramatic loss of engrafted murine NSCs with disease progression. This reduction in engrafted cell survival must be caused by the non-conducive microenvironment in the ALS spinal cord, as identical experiments in wild-type mice did not show such cell loss, ruling out the host antigraft immune rejection as primary mechanism. Li et al. (2005) have reported a failure of immortalized human neuronal progenitor xenografts in the spinal cord of Sprague-Dawley rats despite immunosuppression. The failure of these grafts was ascribed to apoptotic cell death and the presence of an innate immune response. In this study, we observed infiltration of mature macrophages in the gray matter of SOD1 G93A ALS mice at the end-stage of the disease. We also observed excessive microgliosis and astrogliosis in the same region. In ALS, neuronal death is associated with a robust multi-phased response by CNS immune cells, microglia, and astrocytes (Hall et al., 1998) , and these responses become more severe as the disease progresses (Alexianu et al., 2001; Chiu et al., 2009; Yamanaka et al., 2008) . This progressive hostile ALS spinal cord microenvironment suggests that careful selection of an immunosuppression strategy that maximizes cell survival will be important for use of engrafted NSCs for motor neuron repair and regeneration. Whether other neural progenitor cell types respond similarly requires further investigation (Corti et al., 2007; Haidet-Phillips et al., 2015) . We observed a poor graft survival of grafted NSCs in SOD1 G93A ALS mice despite the fact that these cells are known to be immunoprivileged and exhibit a low expression of major histocompatibility complex (MHC) antigens (Hori et al., 2003) . However, exposure of NSCs to proinflammatory cytokines including interferon-γ (IFN-γ) may result in upregulation of the expression of MHC antigens (Hori et al., 2003) , making them a target for the host immune response. In ALS, interferon signaling in astrocytes is triggered by pathologic changes in motor neurons (Wang et al., 2011 ) that can lead to higher levels of IFN-γ in the spinal cord (Aebischer et al., 2012) . Similarly, the blood-spinal cord barrier in ALS becomes impaired at an early stage of the disease and worsens with disease progression (Garbuzova-Davis et al., 2007; Zhong et al., 2008) . This barrier disruption may potentially expose engrafted NSCs to the host immune system and lead to cell death. For evaluating functional outcome, a limitation of our study was the use of the rotarod test as the only behavioral test for cervical spinal cord function. Further studies should be performed using a more comprehensive battery of behavioral tests, combined with longitudinal imaging of cells transplanted at multiple levels of the spinal cord. In summary, our present findings that the ALS disease progression severely affects NSC survival calls for additional approaches to protect engrafted cells from the hostile ALS microenvironment.
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